NCT03965234View on ClinicalTrials.gov

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 16, 2020

Primary Completion Date

May 25, 2029

Study Completion Date

May 25, 2030

Conditions

Metastatic Bone SarcomaMetastatic Malignant Neoplasm in the LungMetastatic Soft Tissue SarcomaMetastatic Unresectable SarcomaResectable SarcomaColorectal Cancer

Interventions

DRUG

Cisplatin

Given via infusion

PROCEDURE

Isolated Chemotherapeutic Lung Perfusion

Undergo pulmonary suffusion

PROCEDURE

Metastasectomy

Undergo metastasectomy

Trial Locations (1)

14263

RECRUITING

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors

lead

Roswell Park Cancer Institute

OTHER

NCT03965234 - Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases | Biotech Hunter | Biotech Hunter